Page 2 - Anna Van Acker News Today : Breaking News, Live Updates & Top Stories | Vimarsana

KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body's immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2 KIRKLAND, QC, March 8, 2021 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Health Canada has approved KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-hig...

Approval Based on Significant Progression Free Survival Findings from Phase 3 KEYNOTE-177 Trial KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the ability of the body’s immune system to help detect and fight tumour cells. 1 An estimated 26,900 Canadians were diagnosed with colorectal cancer in 2020, with an average of 73 Canadians diagnosed daily. 2  Merck known as MSD outside the United States … Approval Based on Significant Progression Free Survival Findings from Phase 3 KEYNOTE-177 Trial KEYTRUDA ® is an anti-PD-1 therapy that works by helping increase the a...

Merck Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnosis and treatment for lung cancer patients Merck Canada and MaRS Discovery District are proud to launch the Lung Cancer Innovation Challenge . The competition challenges Ontario -based innovators to identify, implement and scale solutions that can enhance an Ontario lung cancer patient’s journey by seeking to reduce … Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnos...